Dasatinib Is Associated with Rapid and Durable Complete Hematologic Responses in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

被引：0
|
作者：
Liu, Delong [1 ]
Matloub, Yousif [2 ]
Mulchopadhyay, Jaydip [2 ]
Liu, David [2 ]
Goldberg, Stuart L. [3 ]
机构：
[1] New York Med Coll, Valhalla, NY 10595 USA
[2] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[3] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：741 / 741
页数：1
相关论文
共 50 条
  • [21] SIX-YEAR FOLLOW-UP OF PATIENTS WITH IMATINIB-RESISTANT OR IMATINIB-INTOLERANT CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING DASATINIB
    Rea, D.
    Vellenga, E.
    Junghanss, C.
    Baccarani, M.
    Kantarjian, H.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    HAEMATOLOGICA, 2012, 97 : 80 - 80
  • [22] Dasatinib Discontinuation in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DASFREE)
    Shah, Neil P.
    Gutierrez, Jose Valentin Garcia
    Jimenez-Velasco, Antonio
    Larson, Sarah M.
    Saussele, Susanne
    Rea, Delphine
    Mahon, Francois-Xavier
    Levy, Moshe
    Gomez-Casares, Maria Teresa
    Pane, Fabrizio
    Nicolini, Franck-Emmanuel
    Mauro, Michael J.
    Sy, Oumar
    Martin-Regueira, Patricia
    Lipton, Jeffrey H.
    BLOOD, 2017, 130
  • [23] Two-year monitoring and treatment patterns in German patients with chronic-phase Chronic Myeloid Leukemia (CP-CML) in a prospective observational study
    Tesch, H.
    Nusch, A.
    Linde, H.
    Sen, G. P.
    Schollmeyer, A.
    Hehlmann, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 178 - 179
  • [24] Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR).
    Piazza, R
    Magistroni, V
    Tornaghi, L
    Andreoni, F
    Bungaro, S
    Cazzaniga, G
    Biondi, A
    Pogliani, E
    Varella-Garcia, M
    Corneo, G
    Gambacorti-Passerini, C
    BLOOD, 2003, 102 (11) : 319B - 319B
  • [25] MINIMUM FOLLOW-UP OF 4 YEARS FOR ONGOING PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) IN A PHASE 1 TRIAL OF PONATINIB
    Talpaz, M.
    Cortes, J. E.
    Kantarjian, H. M.
    Shah, N. P.
    Bixby, D. L.
    Flinn, I. W.
    O'Hare, T. J.
    Hu, S.
    Rivera, V. M.
    Clackson, T.
    Conlan, M. G.
    Haluska, F. G.
    Druker, B. J.
    Deininger, M. W.
    Mauro, M. J.
    HAEMATOLOGICA, 2015, 100 : 65 - 66
  • [26] Opportunistic Infections Are Uncommon with Dasatinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
    Al-Ameri, Ali
    Kantarjian, Hagop
    Borthakur, Gautam
    Bahceci, Erkut
    Szatrowski, Ted
    Damokosh, Andrew
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 459 - 459
  • [27] Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
    Hochhaus, Andreas
    Kantarjian, Hagop M.
    Baccarani, Michele
    Lipton, Jeffrey H.
    Apperley, Jane F.
    Druker, Brian J.
    Facon, Thierry
    Goldberg, Stuart L.
    Cervantes, Francisco
    Niederwieser, Dietger
    Silver, Richard T.
    Stone, Richard M.
    Hughes, Timothy P.
    Muller, Martin C.
    Ezzeddine, Rana
    Countouriotis, Athena M.
    Shah, Neil P.
    BLOOD, 2007, 109 (06) : 2303 - 2309
  • [28] Dasatinib vs imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): DASISION European subpopulation analysis
    Stegelmann, F.
    Mayer, J.
    Warzocha, K.
    Huguet, F.
    Steegmann, J. L.
    Gambacorti-Passerini, C.
    Lofgren, C.
    Dejardin, D.
    Hochhaus, A.
    ONKOLOGIE, 2012, 35 : 47 - 48
  • [29] Predictors of Long-Term Cytogenetic Response Following Dasatinib Therapy of Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP)
    Jabbour, Elias
    Bahceci, Erkut
    Zhu, Chao
    Lambert, Alexandre
    Cortes, Jorge
    BLOOD, 2009, 114 (22) : 1278 - 1278
  • [30] Early Optimization of Imatinib Therapy in Patients Newly Diagnosed with Chronic-Phase Chronic Myeloid Leukemia (CP-CML). A Study of the Spanish PETHEMA Group.
    Cervantes, Francisco
    Lopez-Garrido, Pilar
    Montero, Maria-Isabel
    Jonte, Femin
    Martinez, Jesus
    Hernan-dez-Boluda, Juan-Carlos
    Calbacho, Maria
    Sureda, Anna
    Perez-Rus, Gloria
    Nieto, Jose
    Perez-Lopez, Cristina
    Roman, Jose
    Gonzalez, Marcos
    Pereira, Arturo
    Colomer, Dolors
    BLOOD, 2009, 114 (22) : 456 - 457
12345